Cargando…
Mesenchymal stromal cell therapy in COPD: from bench to bedside
COPD is the most frequent chronic respiratory disease and a leading cause of morbidity and mortality. The major risk factor for COPD development is cigarette smoke, and the most efficient treatment for COPD is smoking cessation. However, even after smoking cessation, inflammation, apoptosis, and oxi...
Autores principales: | Antunes, Mariana A, Lapa e Silva, José Roberto, Rocco, Patricia RM |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652911/ https://www.ncbi.nlm.nih.gov/pubmed/29081655 http://dx.doi.org/10.2147/COPD.S146671 |
Ejemplares similares
-
Umbilical cord mesenchymal stromal cells—from bench to bedside
por: Chetty, Shashank, et al.
Publicado: (2022) -
Bench-to-bedside review: The role of glycosaminoglycans in respiratory disease
por: Souza-Fernandes, Alba B, et al.
Publicado: (2006) -
Basic Biology and Clinical Application of Multipotent Mesenchymal Stromal Cells: From Bench to Bedside
por: Kuçi, Selim, et al.
Publicado: (2012) -
Angiogenesis in gastrointestinal stromal tumors: From bench to bedside
por: Papadakos, Stavros P, et al.
Publicado: (2022) -
CDG Therapies: From Bench to Bedside
por: Brasil, Sandra, et al.
Publicado: (2018)